Castle Biosciences Inc - Ordinary Shares

Castle Biosciences Inc - Ordinary Shares is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. This stock has a reasonable momentum. Castle Biosciences Inc - Ordinary Shares has good growth characteristics. Castle Biosciences Inc - Ordinary Shares is not very popular among insiders. Castle Biosciences Inc - Ordinary Shares is a mediocre stock to choose.
Log in to see more information.
CSTL Fundamental Data by TradingView

News

Castle Biosciences: DecisionDx -Melanoma can precise predict SLN positivity risk
Castle Biosciences: DecisionDx -Melanoma can precise predict SLN positivity risk

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

DecisionDx-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
DecisionDx-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms

Business Wire Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study further demonstrating that...\n more…

Zurcher Kantonalbank Zurich Cantonalbank Increases Position in Castle Biosciences, Inc. (NASDAQ:CSTL)
Zurcher Kantonalbank Zurich Cantonalbank Increases Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Ticker Report Zurcher Kantonalbank Zurich Cantonalbank grew its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 10.7% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor...\n more…

Castle Biosciences: New study shows DecisionDx-SCC test benefits SCC patients
Castle Biosciences: New study shows DecisionDx-SCC test benefits SCC patients

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Study Confirms the Ability of Castle Biosciences' DecisionDx-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carci
Study Confirms the Ability of Castle Biosciences' DecisionDx-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carci

Business Wire Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study in Future Oncology further...\n more…

Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High at $30.50
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High at $30.50

Ticker Report Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) shares reached a new 52-week high on Friday . The stock traded as high as $30.50 and last traded at $29.92, with a volume of 7486 shares...\n more…